Premium
Dopamine receptor‐mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time
Author(s) -
Taymans JeanMarc,
Kia Hossein Kami,
Claes Robby,
Cruz Catarina,
Leysen Josée
Publication year - 2004
Publication title -
european journal of neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.346
H-Index - 206
eISSN - 1460-9568
pISSN - 0953-816X
DOI - 10.1111/j.0953-816x.2004.03336.x
Subject(s) - rgs2 , dopamine receptor d2 , dopaminergic , dopamine receptor , quinpirole , dopamine receptor d1 , biology , medicine , endocrinology , dopamine , microbiology and biotechnology , g protein , signal transduction , gtpase activating protein
RGS2 and RGS4 mRNAs are regulated in the rat striatum by dopaminergic agents. The present study further characterizes this regulation in three experiments. First, dopamine type 1 (receptor) (D1)‐ and dopamine type 2 (receptor) (D2)‐mediated regulator of G‐protein signalling (RGS) gene regulation was investigated in animals with deleted ascending dopaminergic pathways. We showed that RGS2 expression is controlled by D1 receptors either by direct action on D1 receptors or indirectly by presynaptic D2 receptors. Conversely, RGS4 gene expression is independent of presynaptic D2 receptors. Second, the study of colocalization between RGS2 or RGS4 and D1 or D2 by double labelling in situ hybridization histochemistry revealed broad expression of RGS2 and RGS4 mRNA in striatal subpopulations with colocalization of RGS2 and RGS4 with both D1 and D2 receptors. Finally, to test how far their gene regulation is temporally concerted, changes in RGS2 and RGS4 mRNA levels were measured in parallel with receptor occupancy by specific dopaminergic drugs at different time‐points. RGS2 was rapidly/transiently up‐regulated by the D1 agonist SKF82958 and the D2 antagonist haloperidol (peak at 0.5 h) and down‐regulated by the D1 antagonist SCH23390 and the D2 agonist quinpirole (trough at 1 and 2 h). RGS4 showed a delayed/transient up‐regulation with SCH23390 and quinpirole (peak at 4 and 2 h) and down‐regulation with haloperidol (trough at 8 h). Depending on the drug used, the degree of receptor occupancy did (D1 agonist and RGS2) or did not (D2 antagonist and RGS2) run parallel to RGS gene expression changes, indicating that certain drug effects are direct and others indirect. The precise control of RGS2 and RGS4 expression by dopamine receptors pleads in favour of their potential contribution to the fine‐tuning of D1 and D2 receptor signalling cascades.